OBJECTIVES This study aimed to investigate factors associated with frailty in patients with mild to moderate Alzheimer's disease (AD). METHODS One hundred fifty-seven outpatients aged 65 years or older with mild to moderate AD were enrolled from January 2018 to December 2018. Cognitive status, depressive mood, activities of daily livings (ADLs), body mass index, handgrip strength (HGS), usual gait speed (UGS), and serum levels of 25-hydroxyvitamin D, hemoglobin (Hb), albumin, and creatinine were assessed. Frailty was defined as a clinical syndrome in which three or more of the following criteria were present fatigue, resistance, ambulation, illness, and unintentional weight loss. RESULTS The prevalence of frailty was 15.9%. Those classified as being frail were significantly older, had worse cognitive function, worse ADLs, slower UGS, and lower level of Hb compared to those classified as being pre-frail and those robust, respectively. The pre-frail group was significantly older, had worse ADLs, and slower UGS compared to the robust group. Both the frail and pre-frail groups had more depressive symptoms and weaker HGS than the robust group. Multiple logistic regression analysis showed that cognitive function, UGS, level of Hb, and depressive symptoms were associated with frailty, and that only depressive symptoms were associated with pre-frailty. CONCLUSIONS Depressive symptoms were a common risk factor for pre-frailty and frailty in patients with AD. Hb levels and UGS were associated with being frail. Preventing frailty in patients with AD should be approached from both physiological and psychological aspects. Edoxaban is licensed in many countries around the world, following successful phase-III trials in stroke prevention in atrial fibrillation (SPAF) and treatment of venous thromboembolism (VTE), but at present, little is known about edoxaban-related bleeding complications in daily care. Using data from a prospective, non-interventional oral anticoagulation registry, we analysed rates, management and outcome of edoxaban-related bleeding. Between 1 October 2011 and 28 February 2019, 996 patients were enrolled in the edoxaban cohort and a total of 891 bleeding events were observed (53.2% ISTH minor, 41.9% clinically relevant non-major and 4.9% major bleeding events). In case of major bleeding, surgical or interventional treatment was performed in 25.0% and prothrombin complex concentrate was given in 2 cases. In the time-to-first-event analysis, 100-patient-year rates of major bleeding were 3.1/100 patient-years (95% CI 2.2-4.2). In the as-exposed analysis, case-fatality rates of edoxaban-associated bleeding leading to hospitalizations were 7.5% and 9.0% at days 30 and 90 post bleeding, respectively. Taken together, our data indicate that, in real life, rates of edoxaban-related major bleeding in line with rates observed in phase III trials and that bleeding pattern, management and outcome of these events are not different from those reported for other direct factor Xa inhibitors. Clinical Trial Notation Dresden NOAC Registry - ClinicalTrials.gov Identifier NCT01588119. INTRODUCTION Timely measurement of direct oral anticoagulants (DOACs) is challenging, though clinically important. We tested the hypotheses, that thromboelastometry is able to detect dabigatran and rivaroxaban and discriminates between dabigatran and rivaroxaban as representatives of the two groups of DOACs. METHODS AND MATERIALS We conducted a prospective-observational study In-vitro dose-effect-curves for rivaroxaban and dabigatran were performed (n = 10). Ex-vivo Patients with indication of DOAC treatment (stroke; dabigatran/rivaroxaban) were included (n = 21). Blood samples were analyzed before first intake, at first estimated peak level and at 24 h after first but before following intake and 3 h after 24 h-intake. Standard and modified thromboelastometric-assays, using low tissue factor concentrations (TFTEM) or ecarin (ECATEM) were used. Receiver-operating-characteristics-curve-analysis (ROC), regression-analysis and two-way-ANOVA were performed. RESULTS In-vitro TFTEM detected dabigatran and rivaroxabaample size. A simple, colorimetric and visual method is described for the determination of cysteamine (CA) using polyvinylpyrrolidone-stabilized silver nanoparticles (PVP-AgNPs) as a colorimetric probe. The sensing method was based on the aggregation of PVP-AgNPs that led to the changes in the color and absorption profile of the probe.  https://www.selleckchem.com/products/bgb-8035.html  The aggregation of PVP-AgNPs in the presence of CA was evidenced by using transmission electron microscopy (TEM), zeta and dynamic light scattering (DLS) measurements. A distinct color transition could be observed with the naked eye from pale yellow color of PVP-AgNPs to purple. PVP-AgNPs probe showed an excellent selectivity towards CA versus other interfering biomolecules, cations and anions. Furthermore, the colorimetric probe had a linear response for CA from 0.1 to 1.0 μM concentration range with the limit of detection (LOD) of 4.9 nM. The prepared probe was successfully utilized for the determination of CA in blood serum as biological samples. In this work, LaFeO3 nanoparticles were fabricated by a facile sol-gel method and applied to degrade tetracycline hydrochloride (TC-HCl) through heterogeneous activation of persulfate under visible-light illumination. The structure, compositions, photocatalytic properties, and morphological features of the as-obtained sample were investigated by XRD, XPS, DRS, and FESEM techniques. Optimizations of dosage of LaFeO3 (0-0.4 g/L), dosage of PS (0-4 g/L), concentration of TC-HCl (10 ppm-80 ppm), and pH of initial solution (2.09-9.59) were conducted. Radical trapping experiments indicated that SO4- was the dominant radical for TC-HCl removal while OH was also involved. In addition, LaFeO3 was proved with excellent stability and reusability in degrading TC-HCl molecules in the Vis/LaFeO3/PS system. The findings of this work revealed the potential application of the Vis/LaFeO3/PS system toward degrading organic pollutants in wastewater. As a persistent organic pollutant, polycyclic aromatic hydrocarbons (PAHs) may still residually pollute industrial sites after relocation. This study investigated the contamination status of PAHs in the topsoils of three industrial legacy sites (the Shougang industrial ruins, the original Beijing coking plant area, and an abandoned gas station) that relocated more than 10 years ago from downtown Beijing. The sources of PAHs in the soil were qualitatively and quantitatively analyzed, and health risks were evaluated for different groups of people. The total concentration of 16 PAHs in the study area ranged from 371.1 ng g-1 to 4073.9 ng g-1. The pollution levels of the three study areas were abandoned gas station > Beijing coking plant > Shougang ruins. In terms of composition, low-ring aromatics accounted for the majority of the detected PAHs, and in the dry season, low-ring aromatics accounted for a higher proportion in the three areas than in the wet season. The comparison of the PAH diagnostic ratio and PMF model verification showed that the sources of PAHs in the Shougang ruins and the Beijing coking plant area were mainly those of biomass and coal combustion, accounting for 66.